Multiple Myeloma Survival Rate With Stem Cell Transplant

The transplant of this kind is the standard treatment for patients with various myeloma.

Multiple myeloma survival rate with stem cell transplant.

There can be a long period of dormancy that could. Multiple myeloma survival rate after stem cell transplant. A stem cell transplant replaces diseased stem cells with healthy ones and is often used to treat this form of cancer. A person with multiple myeloma is likely to have a low blood count.

A relative survival rate compares people with the same type and stage of cancer to people in the overall population. In some cases a bone marrow or stem cell transplant is an option. Treatment options for myeloma have expanded in. Patients with multiple myeloma live longer without their disease progressing if they get a stem cell transplant compared with patients who received chemotherapy alone.

Multiple myeloma isn t considered curable but symptoms wax and wane. Before the transplant drug treatment is used to reduce the number of myeloma cells in the patient s body. The widespread use of high dose therapy and autologous stem cell transplantation asct as well as the introduction of novel agents have significantly improved outcomes in multiple myeloma mm enabling long term survival. Findings from a phase 3 clinical trial note that patients with multiple myeloma who receive upfront autologous stem cell transplant asct typically live longer without disease.

All things considered while the autologous transplant can make the myeloma go away for a period of time even years it does not cure the growth and inevitably the myeloma back. The high doses of chemo or radiation used to treat a multiple myeloma relapse can kill the stem cells in your bone marrow. We here analyze factors influencing survival in 865 newly diagnosed mm patien. Autologous stem cell transplantation autosct has an important role in the treatment of patients with symptomatic multiple myeloma mm.

See drug therapy for multiple myeloma stem cell transplants sct can be autologous or allogeneic. Older patients and those with low risk disease show the greatest gains over time while people with high risk factors showed the least change its researchers said. To protect them your doctor removes stem cells.